Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-GVHD: Rituximab, Ciclosporine, and Corticosteroids for First-Line Treatment of Chronic GVHD
NCT01135641Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Jun 2010
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by CHU de Nantes. Started Jun 2010; status: completed.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT01135641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01135641.